Oncotype DX 
Genomic Prostate Score® Test


The Oncotype DX Genomic Prostate Score (GPS™) test is a genomic assay designed for men with low-, intermediate-, and high-risklocalized prostate cancer to help guide treatment decisions at the time of diagnosis.1-23 The test analyzes prostate cancer gene activity to predict disease aggressiveness and provide clinically meaningful endpoints.

Reports That Matter

With two tailored reports, the GPS test provides useful information for when active surveillance may be an appropriate decision for low- to intermediate-risk patients, as well as risk estimates to help inform your treatment decisions for higher-risk patients.1-23

The GPS test report helps facilitate discussions by consolidating key prostate cancer characteristics in a single document for ease of reference during management conversations.

Clinical Evidence and Endpoints Matter

The Oncotype DX GPS test has been developed and studied in over 10,000 patients.1-12,14-23 The test provides crucial endpoints with actionable data to help address the needs of each patient.

Adverse Pathology: Predicts the risk of aggressive disease based on biopsy1,2

Metastasis and Prostate Cancer Death: Long-term endpoints predict future tumor behavior to ease patient concerns and offer confidence in clinical decisions3,14,15,23

Talking to Your Patients

It can be overwhelming for patients to remember all the information they are told during an office visit. During patient conversations, you can go over these points:

  • Resources are available that may be helpful in discussing prostate cancer and genomic testing
  • A genomic test measures the expression of genes within a sample of tumor tissue1
  • The Oncotype DX GPS test is a genomic test, and the results can help determine how aggressive the patient’s cancer is1

Personalized Results Matter

  • Easy-to-understand GPS test result ranging from 0 to 100 that corresponds to the biologic aggressiveness of the tumor
  • 17-gene signature, including 12 cancer-related genes representative of 4 key biological pathways and 5 reference genes
  • Predicts the likelihood of adverse pathology, prostate cancer death, and metastasis within 10 years1-3,15,23


The test is well suited for patients with localized prostate cancer, from clinically low-risk through high-risk.

How To Order Oncotype DX

We make your ordering experience efficient. You can order a test through the physician portal, and we’ll help you every step of the way.

  1. Foxman B, et al. The Epidemiology of Urinary Tract Infection. Nat Rev Urol 2010; 7: 653-60.
  2. Flores-Mireles AL, et al. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. Rev Microbiol 2015; 13: 269-84.
  3. Sathiananthamoorthy S, Malone-Lee J, Gill K, et al. Reassessment of Routine Midstream Culture in Diagnosis of Urinary Tract Infection. J Clin Microbiol. 2019;57(3):e01452-18. Published 2019 Feb 27. doi:10.1128/JCM.01452-18.
  4. Annemarie D, David B, Kelly R, Natalie L, Meghan C, et al. Utilization of M-PCR and P-AST for Diagnosis and Management of Urinary Tract Infections in Home-Based Primary Care. JOJ Urology & Nephrology, 2020; 7(2): 555707. DOI: 10.19080/JOJUN.2020.07.555707